Research·October 16, 2026 at 11:32 AM EDT·1 source
Novartis scraps Fabhalta study in lupus nephritis
NVS -3.3%
NVS · last 30 trading days+2.9% since the news
News
What happened
- Novartis terminated a mid-stage Fabhalta trial in lupus nephritis, according to a federal clinical trials database.
- The company cited “strategic considerations” for ending the study.
- Fabhalta, also known as iptacopan, is a key part of Novartis’ portfolio.
Why it matters
The termination affects development prospects for Fabhalta in lupus nephritis and may influence assessments of Novartis’ pharmaceutical pipeline and portfolio strategy.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 13Novartis quietly returns a key antibiotic to US market
- First reported by Endpoints NewsOct 16Novartis scraps Fabhalta study in lupus nephritis
Who is involved
Novartis scraps Fabhalta study in lupus nephritisNovartisNVSFabhalta
Company
Sources (1)
- Endpoints NewsOct 16Novartis scraps Fabhalta study in lupus nephritis
Related
- Oct 23 · Bristol Myers reveals autoimmune CAR-T trial death, explains summertime pause
- Oct 23 · Novartis multiple sclerosis treatment cuts rates of relapse in pivotal trials
- Oct 23 · Novartis Multiple Sclerosis Pill Missed Expectations in Key Study
- Oct 23 · Novartis’ Kisqali Cuts Death Risk 19% in Breast Cancer Study
- Oct 22 · Roche talks up Phase 3 success rate as it unveils pipeline cuts
- Oct 13 · Novartis quietly returns a key antibiotic to US market
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.